Professional
Added to YB: 2025-07-03
Pitch date: 2025-06-30
ATHA [neutral]
Athira Pharma, Inc.
+29.33%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Company Info
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
Market Cap
$15.8M
Pitch Price
$3.00
Price Target
0.48 (-88%)
Dividend
N/A
EV/EBITDA
-0.02
P/E
-0.42
EV/Sales
N/A
Sector
Pharmaceuticals
Category
value
Clark Street Value Mid Year 2025 Portfolio Review: Current Position - Athira Pharma, Inc.
ATHA (holding update): Trading at $0.31/share vs $0.48/share liquidation value ($33.7MM NCAV, burn $15MM). Perspective Advisors (14% owner) discussing reverse merger. BML (8%) pushing for liquidation. Phase 1 ALS therapy (ATH-1105) ongoing with potential ALS patient dosing in 2023. High burn rate (~$9MM/quarter).
Read full article (1 min)